Literature DB >> 15491992

Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme.

Zippi Bercovich1, Chaim Kahana.   

Abstract

Ornithine decarboxylase (ODC) is the most notable example of a protein degraded by the 26 S proteasome without ubiquitination. Instead, ODC is targeted to degradation by direct binding to a polyamine-induced protein termed antizyme (Az). Antizyme inhibitor (AzI) is an ODC-related protein that does not retain enzymatic activity yet binds Az with higher affinity than ODC. We show here that like ODC, AzI is also a short-lived protein that undergoes proteasomal degradation. However, in contrast to ODC degradation, the degradation of AzI is ubiquitin-dependent and does not require interaction with Az. Moreover, Az binding actually stabilizes AzI by inhibiting its ubiquitination. Substituting the C terminus of AzI with that of ODC, which together with Az constitutes the complete degradation signal of ODC, does not subvert AzI degradation from the ubiquitin-dependent mode to the Az-dependent mode, suggesting dominance of the ubiquitination signal. Our results suggest opposing roles of Az in regulating the degradation of AzI and ODC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491992     DOI: 10.1074/jbc.M410234200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Authors:  Andrew J Paris; Zohar Snapir; Cindy D Christopherson; Shirley Y Kwok; Ursula E Lee; Zahra Ghiassi-Nejad; Peri Kocabayoglu; John J Sninsky; Josep M Llovet; Chaim Kahana; Scott L Friedman
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

2.  Evolutionary specialization of recoding: frameshifting in the expression of S. cerevisiae antizyme mRNA is via an atypical antizyme shift site but is still +1.

Authors:  Ivaylo P Ivanov; Raymond F Gesteland; John F Atkins
Journal:  RNA       Date:  2006-01-23       Impact factor: 4.942

3.  Placing a disrupted degradation motif at the C terminus of proteasome substrates attenuates degradation without impairing ubiquitylation.

Authors:  Omri S Alfassy; Itamar Cohen; Yuval Reiss; Boaz Tirosh; Tommer Ravid
Journal:  J Biol Chem       Date:  2013-03-21       Impact factor: 5.157

4.  Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Authors:  Leilei Chen; Yan Li; Chi Ho Lin; Tim Hon Man Chan; Raymond Kwok Kei Chow; Yangyang Song; Ming Liu; Yun-Fei Yuan; Li Fu; Kar Lok Kong; Lihua Qi; Yan Li; Na Zhang; Amy Hin Yan Tong; Dora Lai-Wan Kwong; Kwan Man; Chung Mau Lo; Si Lok; Daniel G Tenen; Xin-Yuan Guan
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

Review 5.  The antizyme family for regulating polyamines.

Authors:  Chaim Kahana
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

Review 6.  Antizyme and antizyme inhibitor, a regulatory tango.

Authors:  Chaim Kahana
Journal:  Cell Mol Life Sci       Date:  2009-04-28       Impact factor: 9.261

7.  Critical factors determining dimerization of human antizyme inhibitor.

Authors:  Kuo-Liang Su; Ya-Fan Liao; Hui-Chih Hung; Guang-Yaw Liu
Journal:  J Biol Chem       Date:  2009-07-27       Impact factor: 5.157

8.  Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function.

Authors:  Shira Albeck; Orly Dym; Tamar Unger; Zohar Snapir; Zippy Bercovich; Chaim Kahana
Journal:  Protein Sci       Date:  2008-03-27       Impact factor: 6.725

9.  Antizyme inhibitor 2 (AZIN2/ODCp) stimulates polyamine uptake in mammalian cells.

Authors:  Andrés J López-Contreras; Bruno Ramos-Molina; Asunción Cremades; Rafael Peñafiel
Journal:  J Biol Chem       Date:  2008-05-28       Impact factor: 5.157

10.  Expression of antizyme inhibitor 2 in mast cells and role of polyamines as selective regulators of serotonin secretion.

Authors:  Kristiina Kanerva; Jani Lappalainen; Laura T Mäkitie; Susanna Virolainen; Petri T Kovanen; Leif C Andersson
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.